U.S. FDA Expands Approval of Pfizer ’s Lorbrena as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
NEW YORK--(BUSINESS WIRE) March 03, 2021 -- The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for Lorbrena® (lorlatinib), expanding the indication to include first-line...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Lung Cancer | New Drug Applications | Pfizer